PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
- Status
- COMPLETED
- Phase
- PHASE2
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2